Accenture enters its October 1 earnings report with the short-seller base continuing to unwind, analyst targets moving sharply higher across multiple firms, and options positioning only modestly defensive, a meaningfully different setup than the one that preceded the September 24 print.
The short-position retreat documented in the previous note has continued. Shares short fell a further 7% on the week to 23.8 million, now 3.84% of the free float. That brings the cumulative unwind to roughly 20% from the early-September peak above 25.9 million, and about 24% below the early-August high near 30 million. The borrow market imposes no friction on that exit: availability has expanded to 1,928% of short interest, up 19% on the week and the loosest reading in the 30-day window shown. Borrowing costs have dropped 13% over the week to 0.43%, the lowest point in that window. The ORTEX short score sits at 38.4, barely changed from last week and firmly in the lower half of the universe. Nothing in this positioning picture reads as a squeeze candidate; it reads as a gradual unwind with a fully open exit door.
Options tell a slightly more cautious story, though not an alarming one. The put/call ratio reached 0.987 on September 29, a touch above its 20-day average of 0.971. The z-score of 1.24 is above the mean but well short of the defensive extremes seen in other earnings setups. The 52-week range runs from 0.499 to 1.007, and the current reading sits near the top of that range without breaching it. Options traders are skewing modestly protective, consistent with heading into a print, not with an outright bearish conviction.
The week's most notable development was a cluster of analyst target increases, all arriving ahead of the October 1 report. JP Morgan raised its target to $200 from $179 while holding Overweight. BMO Capital lifted to $200 from $150. Susquehanna moved to $153 from $140, maintaining Neutral. Alongside those came a Guggenheim downgrade to Neutral from Buy. The consensus mean target is $193, against a current price of $177.12, implying roughly 9% nominal upside. Most targets have been reset materially higher in the past two weeks, yet the stock is down 3.6% on the week and 6.6% over the past month. The gap between target momentum and price momentum is the defining tension. Valuation multiples reflect the compression: the trailing P/E has fallen roughly 1.7 points over 30 days to 11.5, and EV/EBITDA dropped half a point to 6.6. The forward earnings momentum score of 97 (top 3% of the universe) and an EV/EBIT percentile rank of 88 suggest the Street still sees the business as high quality; the market is simply paying less for it.
The bull and bear cases heading into the print are clearly defined. Bulls point to F3Q26 revenue of $18.7 billion, up 6% in dollar terms, a 20 basis point operating margin expansion to 17%, EPS of $3.80 up 9%, and 100 new advanced AI projects in the quarter. Bears note that F4Q26 organic growth is tracking below 1% despite easier comparisons, bookings fell 3% to $19.3 billion, and management has flagged approximately $400 million in Middle East sales impact plus multiple large Managed Services wins pushed into FY27. The October 1 print will be the first chance to see whether the bookings trend or the margin discipline is the more durable signal.
Looking at how ACN has traded around recent reports: the September 24 print produced a 4% one-day decline. The June 18 report was far more severe, with an almost 20% one-day drop. The June 25 print was effectively flat on the day before recovering 6% over five sessions. Peers have had a rough week in sympathy: CTSH fell 3.1%, EPAM dropped 3.9%, and GLOB was down 3.1%, while Gartner was the lone exception, up 4% on the week. The broad peer weakness suggests sector-level caution rather than ACN-specific selling pressure into the print.
The key question for October 1 is whether management can show that the bookings trajectory is stabilising, or whether the FY27 deferrals point to a structural elongation of deal cycles that the freshly raised analyst targets have not yet priced in.
See the live data behind this article on ORTEX.
Open ACN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
